Michael W. Konstan, Jeffrey S. Wagener, Donald R. VanDevanter, David J

Slides:

Advertisements

Similar presentations

J.H.K. Hull, W. Tucker, A.G. Hatrick, R.K. Knight, T.B.L. Ho

Advertisements

Comparing age of cystic fibrosis diagnosis and treatment initiation after newborn screening with two common strategies Don B. Sanders, Huichuan J. Lai,

Effect of dornase alfa on inflammation and lung function: Potential role in the early treatment of cystic fibrosis Michael W. Konstan, Felix Ratjen

Donald R. VanDevanter, David J. Pasta, Michael W. Konstan

Effects of ivacaftor on severely ill patients with cystic fibrosis carrying a G551D mutation Helge Hebestreit, Annette Sauer-Heilborn, Rainald Fischer,

The prevalence of “risky behaviour” in adults with cystic fibrosis

Serology as a diagnostic tool for predicting initialPseudomonas aeruginosa acquisition in childrenwith cystic fibrosis Cori Daines, Donald VanDeVanter,

Zhumin Zhang, Suzanne M. Shoff, HuiChuan J. Lai

A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation.

Use of high-dose ibuprofen in a pediatric cystic fibrosis center

Zachary M. Sellers, Lori McGlocklin, Andrea Brasch

Risk factors for age at initial Pseudomonas acquisition in the cystic fibrosis epic observational cohort Margaret Rosenfeld, Julia Emerson, Sharon McNamara,

Probability of IV antibiotic retreatment within thirty days is associated with duration and location of IV antibiotic treatment for pulmonary exacerbation.

How does heart rate recovery after sub-maximal exercise correlate with maximal exercise testing in children with CF? Sarah P. Cohen, David M. Orenstein

J.H.K. Hull, W. Tucker, A.G. Hatrick, R.K. Knight, T.B.L. Ho

Measuring and improving respiratory outcomes in cystic fibrosis lung disease: Opportunities and challenges to therapy Edith T. Zemanick, J. Kirk Harris,

Measures of body habitus are associated with lung function in adults with cystic fibrosis: A population-based study Doug L. Forrester, Alan J. Knox,

Up-to-date and projected estimates of survival for people with cystic fibrosis using baseline characteristics: A longitudinal study using UK patient registry.

Design and powering of cystic fibrosis clinical trials using pulmonary exacerbation as an efficacy endpoint D.R. VanDevanter, A. Yegin, W.J. Morgan,

Laura Viviani, Baroukh M. Assael, Eitan Kerem

Cirrhosis and other liver disease in cystic fibrosis

Katelyn Krivchenia, Don Hayes, Joseph D. Tobias, Dmitry Tumin

John Widger, Sarath Ranganathan, Philip J. Robinson

The ease of breathing test tracks clinical changes in cystic fibrosis

Rate of improvement of CF life expectancy exceeds that of general population— Observational death registration study Matthew N. Hurley, Tricia M. McKeever,

Clinical outcomes in cystic fibrosis patients with Trichosporon respiratory infection Charles R. Esther, Rongpong Plongla, Alan Kerr, Feng-Chang Lin,

Feasibility of using pedometers to measure daily step counts in cystic fibrosis and an assessment of its responsiveness to changes in health state Bradley.

D. Stevens, P.J. Oades, N. Armstrong, C.A. Williams

Vitamin A and lung function in CF

A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation.

The predictive potential of the sweat chloride test in cystic fibrosis patients with the G551D mutation Verena I. Seliger, David Rodman, Fredrick Van.

Exercise-induced hypoxemia and cardiac arrhythmia in cystic fibrosis

Pulmonary nocardiosis in cystic fibrosis

A.H. Gifford Journal of Cystic Fibrosis

Economic effects of an eradication protocol for first appearance of Pseudomonas aeruginosa in cystic fibrosis patients: 1995 vs. 2009 Yolanda P. Lillquist,

Physiologic endpoints for clinical studies for cystic fibrosis

Correlation of sweat chloride and percent predicted FEV1 in cystic fibrosis patients treated with ivacaftor Meredith C. Fidler, Jack Beusmans, Paul Panorchan,

E. Tschiedel, H. Grasemann, F. Ratjen Journal of Cystic Fibrosis

Colon Cancer in Cystic Fibrosis patients: Is this a growing problem?

Nasal polyposis in lung transplant recipients with cystic fibrosis

Narelle S. Cox, Jennifer Follett, Karen O. McKay

Design and powering of cystic fibrosis clinical trials using rate of FEV1 decline as an efficacy endpoint M.W. Konstan, J.S. Wagener, A. Yegin, S.J.

Effect of ivacaftor in patients with advanced cystic fibrosis and a G551D-CFTR mutation: Safety and efficacy in an expanded access program in the United.

Association between the introduction of a new cystic fibrosis inhaled antibiotic class and change in prevalence of patients receiving multiple inhaled.

Australian epidemic strain pseudomonas (AES-1) declines further in a cohort segregated cystic fibrosis clinic Amanda L. Griffiths, Danielle F. Wurzel,

Respiratory pathogens mediate the association between lung function and temperature in cystic fibrosis Joseph M. Collaco, Karen S. Raraigh, Lawrence.

Trends in pathogens colonising the respiratory tract of adult patients with cystic fibrosis, 1985–2005 F.A. Millar, N.J. Simmonds, M.E. Hodson Journal.

A new method of sweat testing: the CF Quantum®sweat test

V. Thompson, N. Mayer-Hamblett, M. Kloster, D. Bilton, P.A. Flume

Serology as a diagnostic tool for predicting initialPseudomonas aeruginosa acquisition in childrenwith cystic fibrosis Cori Daines, Donald VanDeVanter,

Comparing age of cystic fibrosis diagnosis and treatment initiation after newborn screening with two common strategies Don B. Sanders, Huichuan J. Lai,

H. White, A.M. Morton, S.P. Conway, D.G. Peckham

J.E. Spahr, R.B. Love, M. Francois, K. Radford, K.C. Meyer

Michael W. Konstan, David J. Pasta, Jeffrey S. Wagener, Donald R

D.F. Waterhouse, A.M. McLaughlin, C.G. Gallagher

Experience using centralized spirometry in the phase 2 randomized, placebo-controlled, double-blind trial of denufosol in patients with mild to moderate.

The role of respiratory viruses in adult patients with cystic fibrosis receiving intravenous antibiotics for a pulmonary exacerbation C. Etherington,

CFTR modulators and pregnancy: Our work has only just begun

Felix Ratjen, Todd Durham, Tomas Navratil, Amy Schaberg, Frank J

Beta-lactam allergy in adults with cystic fibrosis

Exercise-induced hypoxemia and cardiac arrhythmia in cystic fibrosis

Treatment intensity and characteristics of MRSA infection in CF

Lutz Goldbeck, Sven Zerrer, Tim G. Schmitz Journal of Cystic Fibrosis

Khin M. Gyi, Margaret E. Hodson, Magdi Y. Yacoub

David Adeboyeku, Sandra Scott, Margaret E. Hodson

Changing thresholds and incidence of antibiotic treatment of cystic fibrosis pulmonary exacerbations, 1995–2005 Donald R. VanDevanter, Eric P. Elkin,

Inhaled amiloride and tobramycin solutions fail to eradicate Burkholderia dolosa in patients with cystic fibrosis Ahmet Z. Uluer, David A. Waltz, Leslie.

Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial Michael W. Konstan, Patrick A. Flume, Matthias.

Absence of a gender gap in survival

Cystic fibrosis and pregnancy in the modern era: A case control study

Presentation transcript:

Risk factors for rate of decline in FEV1 in adults with cystic fibrosis Michael W. Konstan, Jeffrey S. Wagener, Donald R. VanDevanter, David J. Pasta, Ashley Yegin, Lawrence Rasouliyan, Wayne J. Morgan Journal of Cystic Fibrosis Volume 11, Issue 5, Pages 405-411 (September 2012) DOI: 10.1016/j.jcf.2012.03.009 Copyright © 2012 European Cystic Fibrosis Society. Terms and Conditions

Fig. 1 Schematic of study design. Journal of Cystic Fibrosis 2012 11, 405-411DOI: (10.1016/j.jcf.2012.03.009) Copyright © 2012 European Cystic Fibrosis Society. Terms and Conditions

Fig. 2 Patient disposition. Journal of Cystic Fibrosis 2012 11, 405-411DOI: (10.1016/j.jcf.2012.03.009) Copyright © 2012 European Cystic Fibrosis Society. Terms and Conditions

Fig. 3 Estimated decline in FEV1% predicted by age group. Vectors representing the observed average changes in FEV1 % predicted over the study period for the two adult age groups in this study are plotted together with 3 vectors previously published for younger patients with CF. For each age group, the line segment is positioned to begin at the mean age at study baseline and extends to cover the central 90% of follow-up (approximately 5years). For example, the line for the age ≥25y group is centered at about age 35 and extends about 5years, but represents the average decline over a 5-year period across all ages 25 and older. Journal of Cystic Fibrosis 2012 11, 405-411DOI: (10.1016/j.jcf.2012.03.009) Copyright © 2012 European Cystic Fibrosis Society. Terms and Conditions

Fig. 4 Results of multivariable models of FEV1 percent predicted by age group. Risk factors remaining in the final multivariable regression (Table 2) are shown in the left column. For a patient in either the 18–24y group (left) or ≥25y group (right), an estimate of the rate of annual decline in FEV1 percent predicted is obtained by summing parameter estimates (labeled “Est.”) associated with each variable state for the patient. The graphical display shows the reference line (mean rate of decline for each age group), the estimated effect of each variable, and the associated 95% confidence interval. Journal of Cystic Fibrosis 2012 11, 405-411DOI: (10.1016/j.jcf.2012.03.009) Copyright © 2012 European Cystic Fibrosis Society. Terms and Conditions